Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 9/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.72 |
| ▸ | CYSLTR2 | Q9NS75 | 7/20 | 0.71 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.67 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.64 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7095887 | 0.88 | CYSLTR1 (0.79) | CYSLTR1GPBAR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL8735648 | 0.88 | CYSLTR1 (0.78) | CYSLTR1GPBAR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL9828870 | 0.87 | CYSLTR1 (0.76) | CYSLTR1GPBAR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL10544473 | 0.86 | CYSLTR1 (0.84) | CYSLTR1GPBAR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL6583310 | 0.86 | CYSLTR1 (0.78) | CYSLTR1GPBAR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL8317460 | 0.85 | CYSLTR1 (0.74) | CYSLTR1GPBAR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL8001866 | 0.85 | CYSLTR1 (0.74) | CYSLTR1GPBAR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL5160956 | 0.85 | CYSLTR1 (0.74) | CYSLTR1GPBAR1CYSLTR2FFAR1AKR1B1 | |
| Hydrogen Sulfide SCHEMBL9818430 | 0.84 | CYSLTR1 (0.76) | CYSLTR1GPBAR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL4848317 | 0.84 | CYSLTR1 (1.00) | CYSLTR1GPBAR1CYSLTR2ALOX5PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101842357-A | Substituted pyrazole derivatives | TAKEDA PHARMACEUTICAL | 2010-09-22 | — | — | CN | disclosed |
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2194045-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-6011033-A | ANTILEUKOTRIENIC ACTION AND ANTIHISTAMINIC ACTION | KOWA CO., LTD. (JP) | 2000-01-04 | — | — | US | disclosed |
| US-5885987-A | ANTIHISTAMINE AGENT FOR TREATING ASTHMA, ANTILEUKOTRIENE AGENT, ANTIALLERGENS | KOWA CO., LTD. (JP) | 1999-03-23 | — | — | US | disclosed |
| US-5756518-A | EXHIBITS ANTILEUKOTRIENIC ACTION AND ANTIHISTAMINIC ACTION; IS USEFUL IN TREATMENT OF ASTHMA | KOWA CO., LTD. (JP) | 1998-05-26 | — | — | US | disclosed |
| EP-0539117-B1 | Compounds useful as leukotriene antagonists | LILLY CO ELI (GB) | 1998-03-11 | — | — | EP | disclosed |
| EP-0799826-A1 | Heteroaryl substituted phenylene derivatives, their preparation and their use as leukotriene receptor antagonists | KOWA CO. LTD. (JP) | 1997-10-08 | — | — | EP | disclosed |
| US-5622969-A | ADMINISTERING TO HUMAN OR ANIMAL SUFFERING FROM ALLERGIC REACTION OF PULMONARY SYSTEM AND OTHER INFLAMMATORY DISORDERS | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| WO-1997012865-A1 | SYMMETRICAL BISHETEROARYL-METHOXYPHENYL-IMINOXYALKYL-CARBOXYLATES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1997-04-10 | — | — | WO | disclosed |
| US-5569764-A | USEFUL FOR TREATING ALLERGIC REACTIONS OF PULMONARY SYSTEM, ALLERGIC SKIN DISEASES, RHEUMATIC FEVER, CYSTIC FIBROSIS, AND VASCULAR DISEASES | ELI LILLY AND COMPANY (US) | 1996-10-29 | — | — | US | disclosed |
| US-5486612-A | FOR TREATING DISEASES WHICH LEUKOTRIENES MEDIATE | ELI LILLY AND COMPANY (US) | 1996-01-23 | — | — | US | disclosed |
| EP-0658554-A1 | N-benzyl dihydroindole LTD4 antagonists | ELI LILLY AND COMPANY (US) | 1995-06-21 | — | — | EP | disclosed |
| US-5410061-A | Leukotriene antagonist | LILLY INDUSTRIES LIMITED (GB) | 1995-04-25 | — | — | US | disclosed |
| EP-0539117-A1 | Compounds useful as leukotriene antagonists | LILLY INDUSTRIES LIMITED (GB) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | AR, NR5A1, NR3C2 | CYSLTR1 660/4885GPBAR1 583/4885CYSLTR2 812/4885 |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | AR, NR5A1, NR3C2 | CYSLTR1 640/4885GPBAR1 573/4885CYSLTR2 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.